Myeloid-derived suppressor cells: linking inflammation and cancer

Journal of Immunology

Volumn 182, Issue 8, 2009, Pages 4499-4506

  Ostrand Rosenberg, Suzanne ^a   Sinha, Pratima ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; BONE MARROW CELL; GRANULOCYTE; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SUPPRESSOR CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASM; REVIEW; T LYMPHOCYTE;

PROTEIN S 100;

ANIMALS; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; MYELOID CELLS; NEOPLASMS; S100 PROTEINS; T-LYMPHOCYTES;

EID: 65249138393     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802740     Document Type: Short Survey

References (99)

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
2. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
3. Shacter, E., and S. A. Weitzman. 2002. Chronic inflammation and cancer. Oncology (Williston Park, N. Y.) 16: 217-226, 229; discussion 230-232.
4. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
5. Garcia-Rodriguez, L. A., and C. Huerta-Alvarez. 2001. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93.
6. Baron, J. A., and R. S. Sandler. 2000. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 51: 511-523. (Pubitemid 30216052)
7. Ellis, L. M., and D. J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of antitumour activity. Nat. Rev. Cancer 8: 579-591.
8. + myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
9. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-952. (Pubitemid 39620069)
10. Marx, J. 2008. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 319: 154-156.
11. Strober, S. 1984. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu. Rev. Immunol. 2: 219-237.
12. + cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1: 95-103.
13. + progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin. Exp. Metastasis 17: 881-888.
14. Young, M. R., and M. A. Wright. 1992. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: γ interferon plus tumor necrosis factor α synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis. Cancer Res. 52: 6335-6340.
15. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678-689. (Pubitemid 32038493)
16. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero. 2009. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58: 49-59.
17. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166. (Pubitemid 46718400)
18. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179. (Pubitemid 351430364)
19. Haile, L. A., R. von Wasielewski, J. Gamrekelashvili, C. Kruger, O. Bachmann, A. M. Westendorf, J. Buer, R. Liblau, M. P. Manns, F. Korangy, and T. F. Greten. 2008. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 135: 871-881, 881.e1-5
20. + population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204: 1463-1474.
21. Brys, L., A. Beschin, G. Raes, G. H. Ghassabeh, W. Noel, J. Brandt, F. Brombacher, and P. De Baetselier. 2005. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 174: 6095-6104. (Pubitemid 40663798)
22. + cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95: 212-220.
23. hi suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179: 5228-5237.
24. Kerr, E. C., B. J. Raveney, D. A. Copland, A. D. Dick, and L. B. Nicholson. 2008. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 31: 354-361.
25. + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176: 2085-2094.
26. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
27. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175: 4583-4592.
28. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64: 6337-6343. (Pubitemid 39129439)
29. Sinha, P., C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna. 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181: 4666-4675.
30. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte- macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553. (Pubitemid 47041228)
31. + cells to differentiate into immune stimulatory dendritic cells. Otolaryngol. Head Neck Surg. 125: 205-212.
32. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann. Otol. Rhinol. Laryngol. 109: 749-754.
33. Zea, A. H., P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65: 3044-3048.
34. Umemura, N., M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, et al. 2008. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukocyte Biol. 83: 1136-1144. (Pubitemid 351960345)
35. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777-2790. (Pubitemid 44511641)
36. Rossner, S., C. Voigtlander, C. Wiethe, J. Hanig, C. Seifarth, and M. B. Lutz. 2005. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35: 3533-3544. (Pubitemid 43025534)
37. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
38. + myeloid cells. Cancer Res. 66: 6807-6815.
39. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
40. Sawanobori, Y., S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. Shono, M. Kitabatake, K. Kakimi, N. Mukaida, and K. Matsushima. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457-5466.
41. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
42. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
43. Bronte, V., P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170: 270-278. (Pubitemid 36026149)
44. Sinha, P., V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513. (Pubitemid 46815102)
45. Bronte, V., P. Serafini, A. Mazzoni, D. M. Segal, and P. Zanovello. 2003. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24: 302-306. (Pubitemid 36694880)
46. Kusmartsev, S., and D. I. Gabrilovich. 2003. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukocyte Biol. 74: 186-196. (Pubitemid 38040415)
47. Mirza, N., M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66: 9299-9307. (Pubitemid 44521152)
48. + T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57: 1493-1504.
49. + T cells. Gastroenterology 135: 234-243.
50. Zhou, R., P. L. He, Y. X. Ren, W. H. Wang, R. Y. Zhou, H. Wan, S. Ono, H. Fujiwara, and J. P. Zuo. 2007. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. Cancer Sci. 98: 882-889. (Pubitemid 46691827)
51. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloidderived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645. (Pubitemid 40094255)
52. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449. (Pubitemid 36951016)
53. + cells. J. Immunol. 161: 5313-5320.
54. + T cells. Blood 96: 3838-3846.
55. + myeloid cells. J. Immunol. 166: 5398-5406.
56. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168: 689-695. (Pubitemid 34049569)
57. + T cell tolerance in cancer. Nat. Med. 13: 828-835.
58. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65: 11743-11751. (Pubitemid 41821736)
59. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752. (Pubitemid 37494166)
60. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11: 6713-6721.
61. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179: 977-983.
62. Pan, P. Y., G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S. H. Chen. 2008. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228.
63. Li, H., Y. Han, Q. Guo, M. Zhang, and X. Cao. 2009. Cancer-expanded myeloidderived suppressor cells induce anergy of NK cells through membrane-bound TGF- β1. J. Immunol. 182: 240-249.
64. Nefedova, Y., S. Nagaraj, A. Rosenbauer, C. Muro-Cacho, S. M. Sebti, and D. I. Gabrilovich. 2005. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65: 9525-9535. (Pubitemid 41508023)
65. Kortylewski, M., M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mule, W. G. Kerr, et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11: 1314-1321. (Pubitemid 41752912)
66. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for downregulation of tumor immunosurveillance. J. Exp. Med. 202: 1627-1633. (Pubitemid 41815868)
67. Grizzle, W. E., X. Xu, S. Zhang, C. R. Stockard, C. Liu, S. Yu, J. Wang, J. D. Mountz, and H. G. Zhang. 2007. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech. Ageing Dev. 128: 672-680.
68. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.
69. Liu, C., S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H. G. Zhang. 2007. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumorbearing host. Blood 109: 4336-4342. (Pubitemid 46743401)
70. Nausch, N., I. E. Galani, E. Schlecker, and A. Cerwenka. 2008. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112: 4080-4089.
71. Stewart, T. J., M. J. Smyth, G. J. Fernando, I. H. Frazer, and G. R. Leggatt. 2003. Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 63: 3058-3060.
72. De Santo, C., M. Salio, S. H. Masri, L. Y. Lee, T. Dong, A. O. Speak, S. Porubsky, S. Booth, N. Veerapen, G. S. Besra, et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118: 4036-4048.
73. Allavena, P., A. Sica, C. Garlanda, and A. Mantovani. 2008. The Yin-Yang of tumorassociated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222: 155-161. (Pubitemid 351430369)
74. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5: 641-654. (Pubitemid 41113195)
75. Kusmartsev, S., and D. I. Gabrilovich. 2002. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51: 293-298. (Pubitemid 34743981)
76. Fichtner-Feigl, S., M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H. J. Schlitt, J. A. Berzofsky, and W. Strober. 2008. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-α2. Cancer Res. 68: 3467-3475.
77. Baniyash, M. 2004. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4: 675-687. (Pubitemid 39223074)
78. Ezernitchi, A. V., I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash. 2006. TCRζ down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-4772.
79. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
80. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175: 8200-8208.
81. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026.
82. Tu, S., G. Bhagat, G. Cui, S. Takaishi, E. A. Kurt-Jones, B. Rickman, K. S. Betz, M. Penz-Oesterreicher, O. Bjorkdahl, J. G. Fox, and T. C. Wang. 2008. Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419.
83. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650. (Pubitemid 36297552)
84. Bunt, S. K., V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg. 2009. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leuk. Biol. In press.
85. Taketo, M. M. 1998. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst. 90: 1609-1620.
86. Taketo, M. M. 1998. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 90: 1529-1536.
87. 2: changes in macrophage suppressor activity. J. Leukocyte Biol. 53: 550-558.
88. Wang, D., and R. N. DuBois. 2008. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 267: 197-203. (Pubitemid 351842211)
89. Rodriguez, P. C., C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, J. Gilbert, and A. C. Ochoa. 2005. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202: 931-939. (Pubitemid 41396893)
90. Ochoa, A. C., A. H. Zea, C. Hernandez, and P. C. Rodriguez. 2007. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13: 721s-726s.
91. Foell, D., H. Wittkowski, T. Vogl, and J. Roth. 2007. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukocyte Biol. 81: 28-37. (Pubitemid 46021248)
92. Foell, D., M. Frosch, C. Sorg, and J. Roth. 2004. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin. Chim. Acta 344: 37-51. (Pubitemid 38626135)
93. Gebhardt, C., J. Nemeth, P. Angel, and J. Hess. 2006. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 72: 1622-1631.
94. Hiratsuka, S., A. Watanabe, H. Aburatani, and Y. Maru. 2006. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8: 1369-1375. (Pubitemid 44835111)
95. Turovskaya, O., D. Foell, P. Sinha, T. Vogl, R. Newlin, J. Nayak, M. Nguyen, A. Olsson, P. P. Nawroth, A. Bierhaus, et al. 2008. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29: 2035-2043.
96. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
97. Markiewski, M. M., and J. D. Lambris. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727. (Pubitemid 47440971)
98. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
99. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.